Crystalline forms of a biphenyl compound

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.

Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS

The invention provides aminotetralin compounds of formula (I): 120-. (canceled)22. The method of wherein Ris —C(O)NH.23. The method of wherein Rand Rare each independently selected from hydrogen claim 21 , benzyl claim 21 , and phenyl claim 21 , or Rand Rtogether with the carbon atom to which they are attached form a cyclohexyl ring.24. The method of wherein Ris —NRR.25. The method of wherein Rand Rare each independently selected from hydrogen claim 24 , Calkyl claim 24 , and benzyl or Rand Rtogether with the nitrogen atom to which they are attached form piperidinyl.26. The method of wherein Ris —OH or —C(O)NH; Rand Rare each methyl or Rand Rare each ethyl; Ris methyl; Rand Rare each hydrogen; and n is 0 and m is 0.27. The method of wherein the medical condition is opioid-induced bowel dysfunction.28. The method of wherein the medical condition is post-operative ileus.30. The method of wherein Rand Rare each independently selected from hydrogen claim 29 , benzyl claim 29 , and phenyl claim 29 , or Rand Rtogether with the carbon atom to which they are attached form a cyclohexyl ring.31. The method of wherein Ris —NRR.32. The method of wherein Rand Rare each independently selected from hydrogen claim 31 , Calkyl claim 31 , and benzyl or Rand Rtogether with the nitrogen atom to which they are attached form piperidinyl.33. The method of wherein Ris —OH or —C(O)NH; Rand Rare each methyl or Rand Rare each ethyl; Ris methyl; Rand Rare each hydrogen; and n is 0 and m is 0. This application claims the benefit of U.S. Provisional Application No. 61/007,127 filed on Dec. 11, 2007, the disclosure of which is incorporated herein by reference in its entirety.1. Field of the InventionThe invention is directed to aminotetralin compounds which are useful as mu opioid receptor antagonists. The invention is also directed to pharmaceutical compositions comprising such compounds, methods of using such compounds for treating or ameliorating medical conditions mediated by mu opioid ...

CRYSTALLINE FORMS OF A BIPHENYL COMPOUND

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder. 1. A crystalline monosulfate salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester , characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 12.6±0.2 , 19.7±0.2 , 23.0±0.2 , and 24.4±0.2.28-. (canceled)9. The crystalline monosulfate salt of claim 1 , wherein the powder x-ray diffraction pattern further comprises diffraction peaks at 2θ values selected from 7.7±0.2 claim 1 , 8.4±0.2 claim 1 , 8.8±0.2 claim 1 , 12.6±0.2 claim 1 , 13.7±0.2 claim 1 , 14.1±0.2 claim 1 , 15.3±0.2 claim 1 , 16.0±0.2 claim 1 , and 20.6±0.2.10. (canceled)11. The crystalline monosulfate salt of claim 1 , characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in .12. The crystalline monosulfate salt of claim 1 , characterized by a differential scanning calorimetry trace which shows a maximum endothermic heat flow at about 76.5° C.13. The crystalline monosulfate salt of claim 1 , characterized by a differential scanning calorimetry trace substantially in accordance with that shown in .1430-. (canceled)31. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline monosulfate salt of .32. The composition of claim 31 , which further comprises a therapeutically effective amount ...

CRYSTALLINE FORMS OF A BIPHENYL COMPOUND

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder. 154-. (canceled)55. A method for treating chronic obstructive pulmonary disease or asthma in a patient , the method comprising administering to the patient a crystalline salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]-methylamino}ethyl)piperidin-4-yl ester and phosphoric acid in a molar ratio of from about 1:1.8 to about 1:2.2; wherein the crystalline salt is characterized by:(a) a powder x-ray diffraction pattern having two or more diffraction peaks at 26 values selected from 6.4±0.2, 7.6±0.2, 8.6±0.2, 13.7±0.2, 15.0±0.2, 19.4±0.2, 21.6±0.2, 22.1±0.2, 22.9±0.2, and 23.7±0.2; or(b) a differential scanning calorimetry trace which shows a maximum endothermic heat flow at about 154.5° C.56. The method of claim 55 , wherein the molar ratio is from about 1:1.9 to about 1:2.1.57. The method of claim 55 , wherein the patient is treated for chronic obstructive pulmonary disease.58. The method of claim 55 , wherein the patient is treated for asthma.59. The method of claim 55 , wherein the crystalline salt is characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 6.4±0.2 claim 55 , 7.6±0.2 claim 55 , 8.6±0.2 claim 55 , 13.7±0.2 claim 55 , 15.0±0.2 claim 55 , 19.4±0.2 claim 55 , 21.6±0.2 claim 55 , 22.1±0.2 claim 55 , 22.9±0.2 claim 55 , and 23.7±0.2.60. The method of claim 59 , wherein the powder x-ray ...

CRYSTALLINE FORMS OF A BIPHENYL COMPOUND

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder. 1. A crystalline freebase of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester , characterized by a powder x-ray diffraction pattern having:(a) two or more diffraction peaks at 2θ values selected from 4.7±0.2, 9.6±0.2, 12.7±0.2, 13.7±0.2, 16.7±0.2, 17.4±0.2, 18.5±0.2, 19.4±0.2, 20.8±0.2, 21.4±0.2, 24.2±0.2, and 25.6±0.2; or(b) two or more diffraction peaks at 2θ values selected from 4.6±0.2, 9.3±0.2, 12.9±0.2, 13.6±0.2, 14.0±0.2, 14.6±0.2, 16.5±0.2, 18.6±0.2, 19.1±0.2, 20.9±0.2, 22.1±0.2, 22.7±0.2, and 25.7±0.2.221-. (canceled)22. The crystalline freebase of claim 1 , wherein the powder x-ray diffraction pattern in (a) comprises diffraction peaks at 2θ values of 4.7±0.2 claim 1 , 18.5±0.2 claim 1 , 20.8±0.2 claim 1 , and 25.6±0.2.23. The crystalline freebase of claim 1 , wherein the powder x-ray diffraction pattern in (a) is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in .24. The crystalline freebase of claim 1 , wherein the compound of (a) is characterized by a differential scanning calorimetry trace which shows a maximum endothermic heat flow at about 102.7° C.25. The crystalline freebase of claim 1 , wherein the compound of (a) is characterized by a differential scanning calorimetry trace substantially in accordance ...

CRYSTALLINE FORMS OF A BIPHENYL COMPOUND

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder. 154-. (canceled)55. A crystalline salt comprising biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester and phosphoric acid in a molar ratio of from about 1:1.8 to about 1:2.2; wherein the crystalline salt is characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 6.4±0.2 , 7.6±0.2 , 8.6±0.2 , 13.7±0.2 , 15.0±0.2 , 19.4±0.2 , 21.6±0.2 , 22.1±0.2 , 22.9±0.2 , and 23.7±0.2.56. The crystalline salt of claim 55 , wherein the molar ratio is from about 1:1.9 to about 1:2.1.57. A crystalline salt comprising biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester and phosphoric acid in a molar ratio of from about 1:1.8 to about 1:2.2; wherein the crystalline salt is characterized by a powder x-ray diffraction pattern comprises diffraction peaks at 2θ values of 15.0±0.2 claim 55 , 19.4±0.2 claim 55 , 21.6±0.2 claim 55 , and 23.7±0.2.58. The crystalline salt of claim 57 , wherein the molar ratio is from about 1:1.9 to about 1:2.1.59. A crystalline salt comprising biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester and phosphoric acid in a molar ratio of from about 1:1.8 to about 1:2.2; wherein the crystalline salt is characterized by a differential scanning ...

CRYSTALLINE FORMS OF A BIPHENYL COMPOUND

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder. 1. A crystalline dioxalate salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester , characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 8.7±0.2 , 14.0±0.2 , 19.4±0.2 , and 22.9±0.2.214-. (canceled)15. The crystalline dioxalate salt of claim 1 , wherein the powder x-ray diffraction pattern further comprises diffraction peaks at 2θ values selected from 7.7±0.2 claim 1 , 13.5±0.2 claim 1 , 14.8±0.2 claim 1 , 15.4±0.2 claim 1 , 15.8±0.2 claim 1 , 23.3±0.2 claim 1 , and 24.6±0.2.16. (canceled)17. The crystalline dioxalate salt of claim 1 , characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in .18. The crystalline dioxalate salt of claim 1 , characterized by a differential scanning calorimetry trace which shows a maximum endothermic heat flow at about 73.7° C.19. The crystalline dioxalate salt of claim 1 , characterized by a differential scanning calorimetry trace substantially in accordance with that shown in .2030-. (canceled)31. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline dioxalate salt of .32. The composition of claim 31 , which further comprises a therapeutically effective amount of an agent selected from βadrenergic receptor ...

Crystalline forms of a biphenyl compound

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.

Short-acting sedative hypnotic agents for anesthesia and sedation

The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.

Novel local anesthetic compounds and uses

Novel compounds, pharmaceutical compositions and methods are disclosed for producing local anesthesia of long-duration. The compounds of this invention are multibinding compounds that comprise from 2 to 10 ligands covalently attached to a linker or linkers, each ligand being capable of binding to a ligand binding site in a voltage-gated Na+ channel to modulate the biological processes/functions thereof.

Novel local anesthetic compounds and uses

Novel compounds, pharmaceutical compositions and methods are disclosed for producing local anesthesia of long-duration. The compounds of this invention are multibinding compounds that comprise from 2 to 10 ligands covalently attached to a linker or linkers, each ligand being capable of binding to a ligand binding site in a voltage-gated Na+ channel to modulate the biological processes/functions thereof.

Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

CRYSTAL FORMS OF A BIFENYL COMPOUND

Formas cristalinas de 1-(2-{[4-(4-carbamoilpiperidin-1-ilmetil)benzoil]metilamino}etil)piperidin-4-iléster de ácido bifenil-2-ilcarbámico, y solvatos aceptables para uso farmacéutico de las mismas. La forma cristalina puede ser una base libre, o una sal como por ejemplo una sal difosfato, monosulfato o dioxalato. Composiciones farmacéuticas que comprenden estos compuestos cristalinos o que se preparan utilizando estos compuestos; procesos e intermediarios para reparar los compuestos cristalinos, y métodos para utilizar estos compuestos para tratar un trastorno pulmonar. Crystalline forms of 1- (2 - {[4- (4-carbamoylpiperidin-1-ylmethyl) benzoyl] methylamino} ethyl) piperidin-4-yl ester of biphenyl-2-ylcarbamic acid, and solvates acceptable for pharmaceutical use thereof. The crystalline form may be a free base, or a salt such as a diphosphate, monosulfate or dioxalate salt. Pharmaceutical compositions comprising these crystalline compounds or which are prepared using these compounds; processes and intermediaries to repair the crystalline compounds, and methods to use these compounds to treat a lung disorder.

Novel therapeutic agents that modulate endothelin receptors

NEW COMPOUNDS AND LOCAL ANESTHETIC USES

Un compuesto multiligazón representado por la fórmula I:(L)p (X)qy las sales farmacéuticamente aceptables de los mismos; donde:cada L es un ligando que puede ser igual o diferente en cada ocurrencia;cada X es un ligante que puede ser igual o diferente en cada ocurrencia;p es un entero desde 2 hasta 4; yq es menor que p;donde cada uno de dichos ligandos comprende un dominio ligando capaz de ligarse a un canal Na+ de compuerta-voltaje de una célula. A multiligazón compound represented by the formula I: (L) p (X) q and the pharmaceutically acceptable salts thereof; where: each L is a ligand that can be the same or different at each occurrence; each X is a binder that can be the same or different at each occurrence; p is an integer from 2 to 4; and q is less than p, where each of said ligands comprises a ligand domain capable of binding to a Na + gate-voltage channel of a cell.

Crystalline forms of a biphenyl compound

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.

Aminotetralin compounds as mu opioid receptor antagonists

The invention provides aminotetralin compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

Novel therapeutic agents that modulate endothelin receptors

Novel multi-binding compounds (agents) which bind endothelin receptors are used to treat disorders affecting the cardiovascular, renal, endocrine and nervous systems in mammals that are mediated by the endothelin receptors, such as congestive heart failure, pulmonary hypertension, cerebral vasospasm following subarachnoid hemorrhage, essential hypertension, myocardial infarction, myocardial ischemia, unstable angina, restenosis, renal failure of ischemic origin, portal hypertension, cardiac hypertrophy, atherosclerosis, eclampsia, cerebrovascular disease, vascular disease, migraines, and auto-immune diseases, such as Morbus Wegener and Morbus Raynaud, to name a few. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes/functions thereof. Each of the ligands, which may be the same or different, is covalently attached to a linker or linkers which may be the same or different to provide for the multi-binding compound. The linker is selected such that the multi-binding compound so constructed demonstrates increased modulation of the biological processes mediated by the endothelin receptor than that provided by the ligands in monomeric form. The invention is also directed to pharmaceutical compositions comprising the multi-binding compounds, methods of inhibiting and treating the disorders mediated by endothelin receptors, and methods of preparing multi-binding compounds of the invention.

2 -aminotetralin derivatives as mu opioid receptor antagonists

crystalline forms of a biphenyl compound

FORMAS CRISTALINAS DE UM COMPOSTO DE BIFENILA. A invençào proporciona formas cristalinas de l-(2-{[4-(4-carbamoilpiperidin-1-ilmetil)benzoil]metilamino}etil) piperidin-4-il éster de ácido bifenil-2-ilcarbâmico e solvatos farmaceuticamente aceitáveis do mesmo. A forma cristalina pode ser uma base livre ou um sal, tal como um sal de difosfato, mono-sulfato ou dioxalato. A invençào também proporciona composições farmacêuticas compreendendo esses compostos cristalinos ou preparadas usando esses compostos; processos e intermediários para o preparo dos compostos cristalinos; e métodos de uso desses compostos para tratar um distúrbio pulmonar. Crystalline forms of a biphenyl compound. The invention provides crystalline forms of 1- (2 - {[4- (4-carbamoylpiperidin-1-ylmethyl) benzoyl] methylamino} ethyl) piperidin-4-yl biphenyl-2-ylcarbamic acid ester and pharmaceutically acceptable solvates thereof. The crystalline form may be a free base or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising such crystalline compounds or prepared using such compounds; processes and intermediates for the preparation of crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.

Crystalline form of aryl aniline beta-2 adrenergic receptor agonist

The invention provides crystalline solvate forms of a salt of a novel β 2 adrenergic receptor agonist. The invention also provides pharmaceutical compositions comprising the solvate forms, formulations containing the pharmaceutical compositions, methods of using the solvate forms to treat diseases associated with β 2 adrenergic receptor activity, and processes useful for preparing such solvate forms.

Aminotetralin compounds as opioid receptor antagonists mu

Un compuesto de la fórmula (I): en la que: R1 es -Un compuesto de la fórmula (I): en la que: R1 es -ORa o -C(O)NRbRc; R2, R3 y R4 son con independenciORa o -C(O)NRbRc; R2, R3 y R4 son con independencia entre sí alquilo C1-3; R5 y R6 se eligen con inda entre sí alquilo C1-3; R5 y R6 se eligen con independencia entre sí entre hidrógeno, bencilo y fenependencia entre sí entre hidrógeno, bencilo y fenilo, dicho fenilo está opcionalmentesustituido porilo, dicho fenilo está opcionalmentesustituido por halógeno, o R5 y R6 junto con el átomo de carbono halógeno, o R5 y R6 junto con el átomo de carbono al que están unidos forman un anillo ciclopentilo al que están unidos forman un anillo ciclopentilo ociclohexilo, R7 se elige entre hidroxi, alcoxi C ociclohexilo, R7 se elige entre hidroxi, alcoxi C1-3 y -NR8R9; R8 y R9 se eligen con independencia 1-3 y -NR8R9; R8 y R9 se eligen con independencia entre sí entre hidrógeno, alquilo C1-6, ciclohexilentre sí entre hidrógeno, alquilo C1-6, ciclohexilo y bencilo, o R8 y R9 junto con elátomo de nitrógo y bencilo, o R8 y R9 junto con elátomo de nitrógeno al que están unidos forman un piperidinilo o peno al que están unidos forman un piperidinilo o piperazinilo, dichos piperidinilo y piperazinilo esiperazinilo, dichos piperidinilo y piperazinilo estánopcionalmente sustituidos por metilo; Ra, Rb y tánopcionalmente sustituidos por metilo; Ra, Rb y Rc son con independencia entre sí hidrógeno o alquRc son con independencia entre sí hidrógeno o alquilo C1-3; n es el número 0, 1, 2, 3 ó 4; y m es elilo C1-3; n es el número 0, 1, 2, 3 ó 4; y m es el número 0 ó 1; en la que los sustituyentes de los número 0 ó 1; en la que los sustituyentes de los centros quirales marcados con un asterisco están ecentros quirales marcados con un asterisco están en la configuración trans; con la condición de que n la configuración trans; con la condición de que si n + m >= 1 y R7 es hidroxi o alcoxi C1-3, entonsi n + m >= 1 y R7 es hidroxi o alcoxi C1-3, ...

Novel local anesthetic compounds and uses

Macrocyclic quinazolinones and their use as local anesthetics

Compounds of formula (I) modulate voltage-gated sodium channels and are useful as local anesthetics

phenylacetic acid ester compounds, pharmaceutical compositions and use of said compounds to prepare a medicament useful for inducing or maintaining anesthesia or sedation

"agentes hipnóticos sedativos de ação rápida para anestesia e sedação". a invenção fornece compostos, composições e métodos úteis para induzir ou manter a anestesia ou sedação geral em mamíferos. "fast acting sedative hypnotic agents for anesthesia and sedation". The invention provides compounds, compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.

Crystalline forms of a biphenyl compound

Short-acting sedative hypnotic agents for anesthesia and sedation

The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.

Short-acting sedative hypnotic agents for anesthesia and sedation

The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.

Short-acting sedative hypnotic agents for anesthesia and sedation

The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.

CRYSTALLINE FORMS OF A BIPHENYL COMPOUND

Crystalline forms of a biphenyl compound

Kristalline formen eines arylanilin-beta-2- adrenergenrezeptor-agonists

Sedative hypnotisch wirkende verbindungen mit kurzer wirkungsdauer zur anaesthesie und sedierung

Kristalline formen einer biphenylverbindung

Forbindelse med kortvirkende sedativ hypnotisk virkning for anestesi og sedatering, anvendelse av forbindelsen, mellomprodukt samt farmasoytisk preparat omfattende forbindelsen

Kortvirkende sedative hypnotika for anestesi og sedatering